Abstract
Presentation Description :
Several pharmacological interventions have been shown to slow myopia progression (atropine, pirenzepine and 7-MX). However, their site and mechanism of action is not well understood, which can limit our ability to comprehensively assess their efficacy and safety profiles or to develop novel variants to increase treatment outcomes and reduce off-target effects. This talk will outline some of the gaps in our knowledge, with a particular focus on atropine (due to its effectiveness and widespread use).
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.